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Recent advances have been made in deﬁning the genetic and molecular basis of dementia with Lewy bodies (DLBs) and related
neurodegenerative disorders such as Parkinson’s disease (PD) and Parkinson’s disease dementia (PDD) which comprise the
spectrum of “Lewy body disorders” (LBDs). The genetic alterations and underlying disease mechanisms in the LBD overlap
substantially, suggesting common disease mechanisms. As with the other neurodegenerative dementias, early diagnosis in LBD
or even identiﬁcation prior to symptom onset is key to developing eﬀective therapeutic strategies, but this is dependent upon
the development of robust, speciﬁc, and sensitive biomarkers as diagnostic tools and therapeutic endpoints. Recently identiﬁed
mutations in the synucleins and other relevant genes in PD and DLB as well as related biomolecular pathways suggest candidate
markers from biological ﬂuids and imaging modalities that reﬂect the underlying disease mechanisms. In this context, several
promising biomarkers for the LBD have already been identiﬁed and examined, while other intriguing possible candidates have
recently emerged. Challenges remain in deﬁning their correlation with pathological processes and their ability to detect DLB and
related disorders, and perhaps a combined array of biomarkers may be needed to distinguish various LBDs.
1.Introduction
Over the past decade, dementia with Lewy bodies (DLBs)
has arguably become the second most common form
of neurodegenerative dementia behind Alzheimer’s disease
(AD). In addition to progressive decline in cognition,
DLB is characterized by ﬂuctuations in cognition with
variations in attention and alertness, recurrent formed visual
hallucinations, visuospatial dysfunction, and spontaneous
parkinsonism. Often, DLB patients also exhibit neuroleptic
sensitivity,transient lossofconsciousness,falls, andrapideye
movement (REM-) sleep behavior disorder [1]. The clinical
separation of DLB from other similar disorders is often
diﬃcultresultinginpoordiagnosticaccuracy,buttherelative
temporal co-occurrence of parkinsonian features with the
typical DLB cognitive and behavioral symptoms such as
visuospatial disturbance strongly suggests the diagnosis.
ClinicalpresentationofDLBisalsoinﬂuencedbytheamount
of AD tau pathology, further complicating the diagnosis
[2]. Approximately 20–40% of Parkinson’s disease (PD)
patients also eventually develop a progressive dementing
illness designated as Parkinson’s disease dementia (PDD)
characterized by a frontal-subcortical clinical presentation
[3]. DLB/Diﬀuse Lewy body disease (DLBD), Lewy body
variant of AD (LBV), and PDD comprise an emerging
spectrum of clinical phenotypes from relatively pure motor
PD to the more predominant cognitive and behavioral
disturbance observed in PDD and DLB, yet the reason for
the variability remains unknown. Despite the heterogeneity
of their clinical phenotypes, a signiﬁcant neuropathological
overlap is observed among these diseases, hence the term
“Lewy body disorders” (LBDs) to collectively describe con-
ditions in which Lewy bodies (LBs) and Lewy neurites (LNs)
predominate as the hallmark histological lesions. Variation
in the distribution of Lewy body pathology is present among
LBDs, with more neocortical and limbic system LB in both2 International Journal of Alzheimer’s Disease
DLB and PDD compared to the brains of PD patients
without cognitive symptoms and greater neuronal loss in
substantia nigra in PDD than DLB [4]. Yet, DLB and overlap
disorders such as LBV, more so than PDD, have β-amyloid
pathology and basal forebrain cholinergic deﬁcit similar to
AD patients [5].
As with other forms of dementia, the pathobiological
changes in LBD likely occur decades prior to the onset of
clinicalsymptoms and correspond to widespread irreversible
neurodegeneration [6, 7]. It is increasingly clear from the
AD therapeutic experience that by the time widespread
neuronal injury ensues, symptomatic cholinergic treatments
are minimally eﬀective at best, and disease-modifying thera-
peutic approaches in trials have thus far proven ineﬀective
at altering disease course or in rescuing diseased brain [8,
9]. To demonstrate eﬃcacy, any potential disease-modifying
therapy in neurodegenerative dementia must be initiated
prior to the expression of the clinical phenotype during the
initial molecularpathogenetic eventsbefore irreversible neu-
ronal damage has occurred. At present, accurately predicting
those individuals at risk for developing neurodegenerative
dementia is challenging, and this places greater urgency on
developing earlier methods of disease detection. Critically
important is not only distinguishing the LBD from AD and
otherforms of dementia, butalso separating DLBsand other
LBDs. Although there are many promising candidates for
LBD, no biomarkers have yet been validated for clinical
diagnostic use, and thus many opportunities exist to develop
such tests. Here, we highlight from the perspective of how
majorgeneticdiscoveriesintheLBDandtheircorresponding
biomolecular processes might translate into useful disease
markers in biological ﬂuids. Because of many common
pathogenetic features among the LBDs, the emerging genetic
inﬂuences found in PD have readily been translated to DLBs
and other LBDs, providing clues to rational approaches
for selecting future DLB and LBD biomarker targets for
exploration. This paper will highlight several PD and DLB
genes and their protein products as candidates for biological
disease markers (Table 1).
2.Amyloidand TauinLewyBodyDisorders
2.1. Amyloid Genetics and Biomarkers in LBD. Aβ,ak e y
component of neuritic plaques in AD brain, is overproduced
leading to various degrees of amyloid aggregation and
synaptic and neuronal toxicity [10]. As indicated previously,
amyloid pathology in the form of neuritic and diﬀuse
plaques can be also found in varying degrees in the brain
tissue of patients with DLB, which may interact with LB
or synuclein pathology or inﬂuence the clinical features of
LBDs[4, 11].The geneticmechanisms ofAβ overproduction
in AD are well established; the βAPP gene (chromosome
21), the ﬁrst identiﬁed AD susceptibility gene, encodes a
transmembranous protein ranging from 695 to 770 residues,
which undergoes a process of regulated intramembranous
proteolysis ultimately releasing Aβ peptides, primarily Aβ42
and Aβ40, as well as other fragments. Aβ is generated by
the concerted action of β-secretase and γ-secretase complex,
while the α-secretase pathway precludes Aβ formation by
cleaving βAPP at a site within the Aβ sequence. Genetic
analysis of early-onset familial AD cases revealed numerous
mutations in the βAPP gene as well as presenilin 1 (PS1;
chromosome 14) and presenilin 2 (PS2; chromosome 1)
genes, all of which accelerate the processing of βAPP, leading
to increased Aβ generation [12]. Speciﬁcally, the βAPP
KM670/671NL (Swedish) mutation aﬀects the β-secretase
site, A692G (Flemish) mutation alters the α-secretase site,
and both V717F (Indiana) and V717I (London) mutations
aﬀect the γ-secretase processing, leading to elevated Aβ
levels. Also important in the Notch developmental signaling
pathway which is analogous to βAPP processing, the pre-
senilins are thought to be a component of the γ-secretase
enzyme complex, which suggests that missense mutations
in the presenilins mechanistically lead to accelerated βAPP
processing to Aβ [13].
Therefore, the abnormal proteolytic cleavage of βAPP
leads to elevated brain Aβ deposition, and as a result,
diminished peripheral levels of Aβ. Reﬂecting a shift from
soluble Aβ to insoluble brain deposits, signiﬁcant decreases
in CSF Aβ42 levels have been demonstrated in AD and
more recently in DLB cases [14]. Parnetti et al. found that
DLB, compared with PD, PDD, and AD patients, showed the
lowest CSFlevelsofAβ42 and,whencombinedwith CSFtau,
diﬀerentiatedDLBfromPDandPDD,butnotfromAD[15].
Also, Spies and colleagues showed a greater decrease in Aβ40
in clinical DLB and vascular dementia patients compared
with control levels and even with AD. Diﬀerentiation of
non-AD dementias such as vascular dementia and DLB
was improved by comparing the ratio of Aβ42 and Aβ40
[16]. More recently, the detection of amyloid in dementia
patients has been greatly enhanced by the use of amyloid-
binding agents such as Pittsburgh compound B [17], which
also demonstrated amyloid burden in DLB. An Australian
study reported more variable cortical PiB binding in DLB
patients than in AD [18], whereas a subsequent examination
of PiB binding in LBDs including DLB, PDD, and PD,
compared with AD and normal patients, showed higher
a m y l o i db u r d e ni nD L Ba n dA Dt h a ni nP D D ,P D ,o rN C
patients [19]. Amyloid load was highest in LBD patients in
the parietal and posterior cingulate regions, corresponding
to visuospatial impairments on neuropsychological testing,
suggesting that amyloid deposition could partly contribute
to the clinical presentation of LBDs.
2.2. Tau Genetics and Biomarkers in LBD. Mutations in
the tau gene on chromosome 17 may also present with
phenotypic features of PDD or DLB, but they diﬀer patho-
logically from these disordersin thatLBs are generally absent
[20]. Tau-bearing neuroﬁbrillary tangles remain one of the
pathological hallmarks of AD butare also central to a diverse
group of disorders termed “tauopathies” which include pro-
gressive supranuclear palsy, corticobasal ganglionic degener-
ation, frontotemporal dementia (FTD) with parkinsonism
linked to chromosome 17, and other disorders [21]. Tau
is a microtubule binding protein, which acts to stabilize
tubulin polymerization in microtubules critical for axonalInternational Journal of Alzheimer’s Disease 3
Table 1: Genetics and biomarkers in LBD.
Biochemical
marker Gene defect Relevance to LB disorders Source of
biomarker
AD lesions Aβ
APP: K670M/N671L and so forth.
PS1: H163R and so forth PS2:
N141I and so forth
Deposited in plaques CSF, plasma
Tau Tauopathy: P301L, N279K, K317M,
and so forth
Found in NFT in AD brain, released after
neuronal damage CSF
PD/DLB
lesions
α-synuclein
(PARK1/4)
A53T, A30P (PD), G209A (DLB),
E46K, triplication (PD & DLB)
Mutation →↑α-syn aggregation.
LB component, toxic oligomers and
protoﬁbrils
CSF, skin
cells, platelets
β-synuclein P123H, V70M (DLB) Inhibit α-syn aggregation: mutant causes
degeneration CSF
γ-synuclein SNP in DLBD Amyloidogenic: aﬀects neuronal and
axonalcytoskeleton
Ventricular
CSF
Proteostasis/
oxidative
stress
Parkin (PARK 2) K161N, W453Stop, 202-203delAG,
M192L, K211N, and so forth
Ubiquitin E3 ligase, LOF mutation in PD
alters mitophagy ND
UCHL-1
(PARK 5) I93M, S18Y (SNP)
Neuronal deubiquitinating hydrolase;
impaired synaptic and cognitive function
in AD & PD
ND
PINK 1 (PARK 6) A168P, A217D, E417G, E240K, and
so forth (PD)
Mitochondrial serine/threonine kinase;
LOF mutation in PD alters mitophagy ND
DJ-1 (PARK7) M26I, D149A, G78G, R98Q (PD),
L166P (PD & DLB)
Redox-dependent chaperone; LOF
mutation in PD CSF, plasma
LRRK2 (PARK 8) G2019S, duplication, triplication
(PD)
Gain of function mutant in PD?DLB:
interacts with α-syn and tau, and with
parkin in apoptotic cell death
ND
Cytoskeletal NF NEFM (PD) Disrupted NF → abnormalaxonal
transport; released in cell damage CSF
Lysosomal
dysfunction GBA 84 dupl G, IVS 2 + 1, N370S, L444P
(PD)
Gaucher’s disease, abnormallysosomal
function/autophagy in PD CSF, plasma
Inﬂammation IL-1α,I L - 1 β,
IL-6, TNFα SNP: IL-1β−511,TNF-α−308
α-syn-induced microglial activation →↑
secretion of neuroinﬂammatory
mediators
CSF
CSF: cerebrospinal ﬂuid; GBA: glucocerebrosidase; Aβ: β-amyloid; NF: neuroﬁlament; ND: not yet determined; PD: Parkinson’s disease;DLB: Dementia with
Lewy body; UCHL1: ubiquitin carboxy terminal hydrolase L1; PINK 1: PTEN-induced putative kinase 1; LRRK2: leucine-rich repeat kinase 2; LOF: loss of
function; SNP: single nucleotide polymorphism.
cytoskeletal integrity and function. In disease, tau protein
truncation at Glu 391 or hyperphosphorylation causes
microtubule destabilization and aggregation of unbound tau
into paired helical ﬁlaments (PHFs) leading to characteristic
tangle formations [22]. Unlike the tauopathies, no direct
pathogenetic tau mutations have been identiﬁed in LBDs,
but tau pathology appears to be a consistent feature among
neurodegenerative dementias including AD and LBDs, and
given the pathological overlap, they might share similar
pathogenetic pathways (reviewed in Stoothoﬀ and Johnson)
[23]. The Ser/Thr kinase and glycogen synthase kinase-
3β (GSK3β), in concert with other molecules such as fyn
kinase, normally regulate tau function but with aberrant
activation accelerate the hyperphosphorylation of tau in
neurodegenerative disease. Similarly, the cell cycle family
kinase and cyclin-dependent kinase 5 (Cdk5/p35), active
duringnormalbraindevelopmentandinvolvedinregulatory
tau phosphorylation during mitosis, may also contribute to
PHF formation.
Consequently, both total tau and hyperphosphorylated
forms have been widely investigated and detected in CSF,
but not serum, by enzyme-linked immunosorbent assay
methods. In the diﬀerentiation of dementia types, Arai et al.
initially reported elevated total CSF tau levels in AD but not
in PD, but subsequently, they showed that total tau was also
increased in DLBatsimilar levelstoAD [24].Yet, othershave
found diﬀerences for both total and phospho-tau (p-tau) in
diﬀerentiating DLB from AD [25], and levels of total tau and
p-tau 181 were signiﬁcantly increased in autopsy-conﬁrmed
DLB patients [26]. In clinically diagnosed dementia cases,
CSF p-tau 231 discriminated AD from non-AD dementias
as a group, where levels were signiﬁcantly higher in AD
patients compared with DLB, FTD, vascular dementia, other
disorders, and control subjects [27]. Separation of DLB
from AD, however, was less robust, provided that CSF p-tau
231 levels were also increased in DLB. Clinically diagnosed
DLB cases also showed elevated levels of CSF p-tau 181
compared with controls [28], and Hampel et al. reported4 International Journal of Alzheimer’s Disease
that p-tau 181 provided the best discrimination of DLB
from AD yielding a sensitivity of 94% and speciﬁcity of 64%
[29]. In autopsy-conﬁrmed DLB and AD patients, however,
sensitivity decreased to 75% and speciﬁcity to 61%, with a
diagnostic accuracy reported as 73% [30].
3.Synucleins:Geneticsto Biomarkersin
theLewyBodyDisorders
3.1. Pathogenetics of Synucleins in LBD
3.1.1. Functions of α-Synuclein. LBs are ﬁlamentous inclu-
sions consisting primarily of the presynaptic protein α-
synuclein (α-syn), which might have several roles in vivo.
Studies demonstrate that it is localized to multiple neural
tissues, including high expression in neocortex and hip-
pocampus, and that expression increases during acquisition-
related synaptic plasticity [31]. Interaction with tubulin
suggests α-syn could be a microtubule-associated protein
similar to tau [32, 33], and it is highly active in various
membrane lipid bilayers such as in presynaptic vesicles
acting as a chaperone for soluble NSF attachment protein
receptor (SNARE) complex formation [34], in neuronal
Golgi apparatus inﬂuencing protein traﬃcking [35]a n d
in the inner membrane of neuronal mitochondrial [36].
T h es y n u c l e i n sm i g h ta c tt op r e s e r v em e m b r a n es t a b i l i t y ,
provide antioxidant function, and assist with membrane
turnover, although the actual role of synucleins remains
elusive [37, 38]. Because of its association with LB and the
tendency to self-aggregate into pathological oligomers and
ultimately ﬁbrillar structures [39], α-syn plays a central role
in the pathogenesis of LBD, hence the alternate designation
“synucleinopathies.” The degree of α-syn immunoreactivity
in cortical LBs correlates with cognitive severity and disease
progression inPDDandDLB[4,40].Also,theproteincanbe
recovered from ﬁlaments in puriﬁed Lewy bodies from PDD
and DLB brain [41], and recombinant α-syn tends to form
Lewy body-like ﬁbrillar structures in vitro [42].
3.1.2. α-Synuclein Mutations in PD and DLB. In the past
decade, tremendous advances have been made in under-
standing the genetic factors inﬂuencing the pathogenesis of
Lewybody disorders. Compelling evidenceforageneticbasis
for PD and DLB followed the discovery of mutations in the
α-syn gene (PARK1/4) in patients with autosomal dominant
familial Parkinson’s disease, and subsequently, mutations
were identiﬁed in patients with both sporadic and familial
DLBs. From a susceptibility marker on chromosome 4q21-
23 that segregated with the PD phenotype in Italian and
Greek kindreds, A53T [43] and A30P [44]w e r et h eﬁ r s t
two missense mutations in α-syn associated with familial
Parkinson’s disease. Clinical analysis of the Italian A53T
mutation revealed phenotypic variability over the disease
course with several individuals demonstrating moderate to
severe dementia [45]. Subsequently, a case of clinically and
pathologically well-characterized DLBD in the United States
andaGreekprobandofDLBwithafamilyhistoryofPDwere
both determined to have the A53T α-syn mutation [46, 47].
Another mutation, E46K, was discovered in a Spanish family
presenting with autosomal dominant DLB [48], and in
genetic studies of a large family with the spectrum of Lewy
body phenotype ranging from PD to DLB, α-syn gene
triplication was described, causing α-syn overproduction
similar to the trisomy eﬀect observed in Down syndrome
patients [49].
Autosomaldominantpointmutationsareshowntoaﬀect
the aggregative properties of α-syn, which has mechanistic
implications forthepathogenesisofLBD.Comparedtowild-
typeα-syn, biophysicalanalysesrevealthatα-syn aggregation
is folding state dependent, where A53T and A30P mutated
proteins cause increased aggregation only from the partially
folded intermediate state and not the monomeric state [50].
A53T α-syn transgenic mice have increased oligomerization
of the protein in brain regions devoid of inclusions as well
as those areas with more abundant lesions and neurodegen-
eration, and consistent with priorbiophysicalﬁndings, α-syn
toxicity in these mice was dependent on the conformation of
intermediate species [51]. In fact, the E46K mutation, as well
as the others not only increase the tendency toward aggre-
gation, but also promote formation of annular protoﬁbrillar
structures, causes pore formation in various membranes and
neuronal damage [52].
3.1.3. β-Synuclein Mutations in DLB. α-Syn is a member of
a larger family of synuclein proteins which also includes β-
synuclein(β-syn) andγ-synuclein(γ-syn). β-syn hasrecently
been implicated in PD and DLB pathogenesis, but its precise
roleindiseaseisstillemerging.Despitehavingstronghomol-
ogy with α-syn, it is not clearly amyloidogenic, but is highly
localized to presynaptic sites in neocortex, hippocampus,
and thalamus like α-syn [53, 54]. Normal β-syn may act
as a biological negative regulator of α-syn. In bigenic α-
syn/β-syn-overexpressing mice and in doubly transfected
culturedcells, β-syn ameliorated amyloidogenicity,neurode-
generative changes, and motor deﬁcits induced by α-syn
overexpression alone [55]. On the other hand, mutated β-
syn leads to neuronal damage and disease and augments
neurodegeneration, perhaps through a loss of its natural
regulator function. Two novel β-syn point mutations,P123H
and V70M, were found in highly conserved regions of the β-
syngeneinrespectivefamilial(P123H)andsporadic(V70M)
DLB index cases [56], where abundant LB pathology and
α-syn aggregation was present without β-syn aggregation.
P123H β-syn overexpression in transgenic mice resulted in
axonal damage, gliosis, profound memory, and behavioral
deﬁcits [57]. These phenomena may involve α-syn, since
bigenic mice overexpressing α-syn with P123H β-syn show
greater deﬁcits compared with monogenic mice and com-
pared with P123H β-syn expressed with α-syn knockout,
implying that the P123H mutation has a synergistic eﬀect
with other synucleinopathies to cause neurodegeneration.
P123H as well as V70M β-syn mutations might also injure
neurons by disrupting normal lysosomal pathways and
corresponding cellular autophagic processes [58].
3.1.4. Association of γ-Synuclein with LBD. Unlike the oth-
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expressed in the cell bodies and axons of primary sensory
neurons, sympathetic neurons, and motor neurons as well
as in brain [59]. In cancer biology, γ-syn is associated with
abnormally altering cellular mitotic checkpoints in various
types of malignancies, making them more aggressively
metastatic [60], but as far as neurodegeneration, it is the
most recent synuclein member to be linked to LBD neu-
ropathologyand the least well understood. Single-nucleotide
polymorphisms in all three synucleins have been associated
with sporadic DLBD, most prominently γ-syn [61], and in
sporadic PD, DLB, and LBV patients, γ-syn antibodies, as
well as β-syn and α-syn reveal unique hippocampal axonal
pathology [62]. In vivo, γ-syn overexpression in trans-
genic mice shows age- and dose-dependent neuronal loss
throughout the neuraxis, especially in spinal motor neurons,
where γ-syn-bearing inclusions, gliosis, and alterations in
heat shock protein and neuroﬁlament structure are found
[63], perhaps suggesting relevance to motor neuron disease
associated with dementia. In vitro evidence further supports
a cytoskeletal role for γ-syn in maintaining neuroﬁlament
structure; γ-syn overexpression in cultured neurons causes
disruption of the neuroﬁlament network by destabilizing the
structuralintegrityofneuroﬁlament-Hallowingdegradation
by calcium-dependent proteases, which has implications for
neurodegeneration [64].
3.2. Synucleins as Biomarkers of LBD
3.2.1. Synucleins in the Extracellular Compartment. Synu-
cleins are known as intracellular molecules, but they also
appear in extracellular and peripheral ﬂuids from active
and passive processes. Evidence suggests that turnover and
secretion of these proteins might occur during normal
cellular processing, releasing synucleins into extracellular
space and hence into peripheral sites. In transfected and un-
transfected cultured neuroblastoma cells, 15kDa α-syn is
released into surrounding media [65], and furthermore, not
onlymonomericα-synbutalsoaggregatedformsaresecreted
inanunconventionalexocyticmannerintoextracellularﬂuid
in response to proteasomal and mitochondrial dysfunction
[66]. Remarkably, Desplats et al. recently showed that
neuronally secreted α-syn can also be taken in endocytically
byotherneuronsorgliaasameansoftransmitting pathology
[67]. Secreted α-syn interacts with various molecules such
enzymes; in cultures, matrix metalloproteinase-3 cleaves
native α-syn to smaller proteolytic fragments that enhance
itsaggregative properties[68]. Whether β-syn and γ-syn also
undergo unconventional exocytosis and secretion remains
unknown, but given structural and functional similarity to
α-syn, the possibility exists. Certainly, synaptic and axonal
damage reﬂecting neurodegeneration may also allow release
of synucleins into the extracellular millieu and access to
peripheral ﬂuids such as CSF and blood.
3.2.2. α-Synuclein as a PD and DLB Biomarker. Multiple
forms of α-syn are released into cerebrospinal ﬂuid (CSF)
and other biological ﬂuids. Full-length α-syn has been
recovered from lumbar CSF from living normal control,
PD and DLB patients [69, 70], and also from postmortem
CSF from DLB and other neurodegenerative diseases [71].
Comparative ﬁndings regarding diﬀerences in CSF α-syn
levels among various neurodegenerative diseases, however,
are diﬃculttointerpretbecauseof inconsistentobservations.
In PD, a smaller early study showed that no diﬀerences in
full-length CSF 19kDa α-syn have been found in relation
to control individuals [69], but a recent eﬀort using a
new Luminex assay in a larger sample controlling for
extraneous inﬂuences showed signiﬁcantly decreased levels
in PD compared to controls with 92% disease sensitivity
and 58% speciﬁcity [72]. Elevated α-syn levels, however,
w e r ef o u n di nD L B ,A D ,a n dv a s c u l a rd e m e n t i aw i t hn o
diﬀerences among them [71]. Perhaps more intriguing,
higher-molecular weight aggregated α-syn species in CSF
might be associated with PD and DLB. Reduced levels of
a2 4 k Dα-syn-immunoreactive band were found in DLB
CSF and correlated directly with declining cognition [73].
Moreover, using a speciﬁc enzyme-linked immunosorbent
assay (ELISA), soluble aggregated α-syn oligomers in CSF
were signiﬁcantly increased in PD patients compared against
control subjects, AD and progressive supranuclear palsy,
and speciﬁcity ranged from approximately 85 to 87%, while
sensitivity was about 53–75% range [74].
Plasma α-syndetectedbyimmunoblottingwas decreased
in PD compared with age-matched control subjects, and
those PD patients with age-at-onset prior to 55 years (early-
onset) had signiﬁcantly lower levels than those with onset
after 55 years of age (late-onset) [75]. In addition, soluble
oligomeric α-syn detected by speciﬁc ELISAwas signiﬁcantly
elevated in plasma from PD. This test demonstrated a
speciﬁcity of approximately 85%, a sensitivity of 53%,
and a positive predictive value of 0.818 [76]. Although
measurement of plasma α-syn appears interesting as a
biomarker, it was reported that skin cells and platelets are
also sources for α-syn, and their levels did not correlate
with disease presence or severity [77]. Moreover, red blood
cells are also a major source of α-syn [78], and thus,
plasma couldbecontaminatedbyα-syn notoriginating from
brain, which might render interpretation of results diﬃcult.
One promising consideration for the future exploration
of α-syn as an LBD biomarker will be the development
of novel imaging compounds and techniques, similar to
amyloid imaging, to speciﬁcally target and visualize α-syn
distribution in the PD and LBD brain. The availability of
such methods will be a signiﬁcant advance in biomarkers for
synucleinopathies.
3.2.3. β-Syn and γ-Syn as Potential Biomarkers in Lewy
Body Disorders. Due to their increasing importance in LBD
pathogenesis, β-syn and γ-syn, as much as α-syn, might
be excellent targets as peripheral markers of disease. As
such, levels of these synucleins might be altered in the
CSF of patients with PD/PDD and DLB, reﬂecting the
underlying degenerative processes in brain. No studies to
date have examined β-syn levels in peripheral ﬂuids in
relation to neurodegenerative disease, but a small study
reported elevated postmortem ventricular CSF γ-syn levels6 International Journal of Alzheimer’s Disease
in DLB,AD,and vasculardementiapatients, with thehighest
levels seen in DLB patients [71]. More detailed examination
of both β-syn and γ-syn as a peripheral disease markers
in well-characterized populations of PD, DLB, and other
disorders is warranted to determine their speciﬁcity and
sensitivity in the synucleinopathies.
4.D J-1intheLewyB odyD isor ders
4.1. Functional Role of DJ-1 in Lewy Body Diseases. Recently,
DJ-1 (PARK 7) has emerged as a signiﬁcant molecular target
of interest in LBD principally because of its genetic associa-
tion with PD and its increasing importance in cellular oxida-
tive neuroprotection. Although its exact role is unknown,
multiple functions have been assigned to the DJ-1 protein.
Described by Nagakubo et al. as a mitogen-dependent
oncogene involved in Ras-related signaling pathways [79],
it shares structural homology with the carboxy-terminal
domain of Escherichia coli HPII catalase and is reported to
possess catalase activity which reduces oxidative stress in
cultured cells [80]. It also binds to and regulates the PIAS
SUMO-1 ligase and is itself posttranslationally modiﬁed by
sumoylation [81, 82]. Of relevance to Lewy body formation
and neurotoxicity,DJ-1 displaysredox-dependentchaperone
activity conferring proper protein folding and thermal sta-
bility,which in fact, also inhibits α-syn aggregation [80]. The
overexpression of DJ-1 in rats protects nigral dopaminergic
neuronsagainstdegenerationinvolving6-hydroxydopamine,
while mutant DJ-1 in mice causes abnormal dopamine
reuptake and susceptibility to 1-methyl- 4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) toxicity [83]. Deletion of DJ-
1 homologs in Drosophila renders them sensitive to H2O2,
paraquat, and rotenone toxicity [84].
4.2. DJ-1 Mutations and Possible Relevance to LBD. No less
than 13 gene mutations have been identiﬁed in DJ-1 in
atypical younger-onset PD patients, but their signiﬁcance to
idiopathic late-onset PD remains uncertain. In autosomal
recessive early-onset PD from consanguineous families, a
complete DJ-1 deletion in a Dutch family and a point
mutation L166P in an Italian case were identiﬁed [85].
When expressed in cultured cells, L166P appears to be a
loss-of-function mutation which leads to DJ-1 functional
instability, degradation by the proteasome system [86, 87],
abnormal translocation of DJ-1 to mitochondria, and loss
of chaperone activity [80]. The importance of DJ-1 gene
alterations in dementia and DLB, however, is uncertain. One
report found no impact on dementia risk of the DJ-1 14kb
deletion [88], and analysis of an insertion/deletion variant
(g.168 185del) in DJ-1 in a larger sample of patients also
showed no association with either PD or DLB compared to
control patients [89]. Given these early negative ﬁndings, the
relevanceofDJ-1geneticmutationstoDLBand otherLBDis
notknown.Atpresent,nopatientharboring aDJ-1mutation
has come to autopsy, so the precise pathology is not known.
AlthoughDJ-1mutantcasesmayultimatelynotbeLBDs,itis
possible that alterations in DJ-1 may somehow inﬂuence the
aggregation of α-syn and LB formation [80]o rc o n t r i b u t et o
pathogenesis by other molecular pathways.
DJ-1isfoundinbrainacrossawiderangeofneurodegen-
erative diseases including PD, FTD, AD, DLB, and LBVAD,
and demonstrates striking association with neuropil threads
and neuroﬁbrillary pathology in neocortex and subcortical
brain regions in these disorders [90]. Interestingly, this
association with tau pathology was seen in DLB and LBV
brains, suggesting that as a chaperone molecule, DJ-1 may
be involved in tangle formation, and the binding of DJ-
1 with these lesions could abolish the normally protective
eﬀect of DJ-1, enhancing oxidative neurotoxicity. Wang et al.
observed that DJ-1 knockout mice have markedly abnormal
hippocampal long-term depression accompanied by a less
severe abnormality in long-term potentiation, which was
reversed by the D2/3agonist quinpirole, indicating that DJ-1
has a role in dopamine-dependent signaling in hippocampal
plasticity [91]. This implies that DJ-1 may be important in
the maintenance of memory and cognition.
4.3. DJ-1 as a Potential Biomarker for Lewy Body Dis-
eases. Given its pathogenetic signiﬁcance, DJ-1 could be a
candidate biological marker for DLB and LB and might
serve as a means of monitoring in vivo oxidative damage
and protein misfolding. Although intracellular and mito-
chondrial in localization, DJ-1 is presumed to be secreted
perhaps speciﬁcally under disease conditions which induce
oxidative damage. Using semiquantitative immunoblotting,
we previouslyidentiﬁedDJ-1inCSFofsporadicPDpatients,
where levels were signiﬁcantly elevated compared with
controls. Levels were higher in the earlier stage PD cohort
(Hoehn-Yahr stages I-II) than in the more severe patients
(Hoehn-Yahr stages III-IV) [92]. Similarly, plasma DJ-1
levels in PD patients were markedly increased compared to
controls, but unlike CSF, levels were relatively higher in late
stage (III-IV) rather than early stage PD (I-II) [93]. The
reason for this diﬀerence between plasma and CSF DJ-1 is
unknown, but we surmised previously that since CSF DJ-1
originates from a central source produced mainly by reactive
glia, early increases in CSF DJ-1 levels probably represent
an early protective response to damage, whereas plasma
DJ-1, like other plasma disease markers, likely represents
peripheral oxidative stress damage. In fact, DJ-1 is secreted
into blood in breast cancer, melanoma, familial amyloid
neuropathy, and stroke [94–96]. In the largest study to date,
Hong et al. developed a more sensitive and quantitative
LuminexassayforCSFDJ-1tocomplementimmunoblotting
mass spectrometric and chromatographic analysis methods
and found decreasing rather than increasing levels of DJ-1
in PD CSF compared with control patients [72]. The 90%
disease sensitivity and 70% disease speciﬁcity for PD using
this method approaches minimal desired parameters for a
clinically useful biomarker for PD. Importantly, the study
highlighted the fact that DJ-1 levels are greatly inﬂuenced
by such variables as the extent of blood contamination and
patient age, which could account for some of the variability
across studies. Of note, DJ-1 is also subject to oxidative
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measured in peripheral ﬂuids as well, as another monitor of
oxidative damage [97]. CSF DJ-1 remains a promising and
perhaps clinically useful biomarker for PD, but as far as DLB
and other LBD, it is unknown whether CSF levels of DJ-
1 are altered. Since plasma DJ-1 is increased in DLB, it is
hypothesized that CSF DJ-1 may also be elevated. Further
investigation will be necessary to clarify the utility of DJ-1
as a biomarker in DLB and LBD.
5.Glucocerebrosidaseasa Novel Biomarkerfor
LewyBodyDisorders
5.1. Glucocerebrosidase Mutations Inﬂuence PD and DLB.
Many clinicopathologic parallels can be drawn between
the lysosomal storage disorders, such as Niemann-Pick,
Sandhoﬀ’s, Tay-Sachs disease and others, and the age-related
neurodegenerative disorders, when considering the aberrant
accumulation of pathological substances (e.g., lysosomal
sphingomyelin in Niemann-Pick disease versus synucleins
in PD and DLB) and the phenotypes of neuronal loss
and cognitive deterioration found in both. Common to
these diseases are abnormalities in lysosomal and autophagic
mechanisms as part of a larger disruption of cellular
proteostasis leading to abnormal storage/accumulation of
toxic materials and neuronal damage. In the past few
years, an altogether unexpected pathogenetic relationship
emerged between Gaucher’s disease (GD), a prototypic
storage disease, and the synucleinopathies. Despite its overall
rarity, GD is the most common inherited lysosomal storage
disease, especially in the Ashkenazi Jewish population. It is
caused by autosomal recessive gene mutations in the gluco-
cerebrosidase (GBA) gene (chromosome 1q21), leading to
eitherpartialorcompletedeﬁciencyofGBA,andhence,toxic
lysosomalaccumulationofitssubstrate,glucosylceramide,in
multiple cell types including neurons [98]. Recent reports
documented an increased incidence of PD in heterozygous
relatives of patients with GD [99, 100], but interest in
this phenomenon was propelled by the ﬁnding that GBA
mutations were in fact more common in PD patients of
Ashkenazi background compared with AD patients and PD
patients in the general population [101–103]. Moreover,
more severe GBA mutations such as 84 dupl G and IVS
2 + 1 were associated with a greater degree of PD risk,
compared with less severe GBA mutations such as N370S
[104]. The relationship between PD and GBA has now been
replicated in much larger international studies with the most
common mutations being L444P and N370S, and about 28
GBA mutations are presently recognized [105].
Interestingly, in a study of British patients with PD and
GBA mutations, all 17 carrier patients demonstrated abun-
dant α-syn neuropathology with Braakstage 5-6 severity and
common neocortical LB pathology. Clinically, these patients
had earlier age at onset, and hallucinations were present
in 45% of patients, while 48% had cognitive impairment
or dementia consistent with PDD [106]. Greater severity
of GBA mutation also predicted the presence of cognitive
impairment in PD patients; 56% of severe GBA mutation
carriers had cognitive impairment compared to 25% of mild
mutation carriers [107]. These observations suggest a much
broader link between GBA mutations and the dementia
phenotype of LBD. In fact, examination of GBA gene
alterations in DLB patients, with and without concomitant
LBV-type AD pathology, showed that the majority of GBA
m u t a t i o n sw e r ef o u n di nD L Bp a t i e n t sr a t h e rt h a ni nP D ,
with a mutation rate in DLB ranging from 18 to 23%
overall [108, 109]. The proportion of DLB patients with
GBA mutations was higher in those with pure neocortical
LB pathology compared to those with mixed LB and AD
pathology and to those with predominantly brainstem LB.
A signiﬁcant association was also found between GBA
mutation status and the presence of LB, indicating that
altered GBA might play a role in their formation and in
synucleinopathy [108].
5.2. Glucocerebrosidase and Chaperone-Mediated Autophagy
in LBD. Important in neurodegeneration, disrupted cellular
proteostasis represents a state in which an imbalance exists
between eﬀective functioning of the innate cytoprotective
machinery and excessive accumulation and aggregation of
abnormally misfolded proteins, leading to neurotoxicity. It
is increasingly apparent that chaperone-mediated autophagy
(CMA) and lysosomal degradation pathways are important
in maintaining cellular proteostasis as part of a larger
network of cellular actions, with particular relevance for
neurodegenerative diseases. Recently, as evidence for CMA
dysfunction in synucleinopathies, a signiﬁcant decrease
in autophagy markers was reported in substantia nigra
from PD brain [110]. Soluble forms of α-syn, including
monomers, oligomers, and even protoﬁbrils, are normally
cleared through the CMA/lysosomal degradation by inter-
acting with the chaperone, heat shock cognate-70, and
becoming internalized into lysosomes via the Lamp-2a
membrane receptor [111, 112]. Studies have indicated that
α-syn shares a common pentapeptide structure with other
lysosomal substrates, designating it as a target for removal
by this pathway [111], and the lysosomal structure is critical
to maintaining the internal acidic environment, allowing
lysosomal hydrolases to degrade α-syn into peptides released
into the cytosol [112]. Mutant GBA could therefore disrupt
lysosomal activity leading to abnormal accumulation of
nondegraded α-syn, which then aggregates to toxic solu-
ble oligomers and protoﬁbrils. Also, abnormalities in the
ubiquitin-proteasome system (UPS) are present in AD and
PD, and GBA alterations might secondarily overwhelm the
ability of UPS to remove accumulated α-syn, promoting
aggregation and neurotoxicity [113]. Pathologically, in GD
with parkinsonism, α-syn-positive inclusions were observed
in neurons in hippocampal CA2-4 regions, while cortical
synuclein pathology was identiﬁed in other GD cases [114].
Further, parkin, an E3 ubiquitin ligase also implicated
in PD, has been shown to aﬀect the stability of mutant
GBA and increase its degradation causing further lysosomal
dysfunction [115].
5.3. Glucocerebrosidase as a LBD Biomarker. Because of
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pathogenesis, the issue arises as to whether the measurement
of GBA activity, or a perhaps other related molecules,
might be utilized as a biological marker. The activity of
peripherally secreted GBA was measured in plasma and
CSF in a 10-month-old female with GD with the aim of
monitoringtheeﬀectofexperimental Cerezymereplacement
therapy [116]. Baseline GBA activity was detected in both
plasma (2.7 × 10−6 U/μL) and CSF (0.096 × 10−6 U/μL),
although CSF activity was several magnitudes lower than
plasma.IntravenousCerezyme,amacrophage-targetedGBA,
rapidly raised the plasma activity within 1 hour and CSF
activity by 2.3-fold at 3 hours, both returning to baseline
after 24 hours. This study suggests the intriguing possibility
that GBA activity, especially in CSF and plasma, might be
useful in monitoring the eﬃcacy of novel therapies involving
CMA and lysosomal function. To extend this observation,
Balducci et al. determined that multiple lysosomal hydro-
lases, including GBA, are signiﬁcantly decreased in the
lumbar CSF of PD patients [117], perhaps supporting a
more widespread lysosomal dysfunction in PD not limited
to GBA alone. In this regard, other lysosomal enzymes such
as mannosidase and β-hexosaminidase might be important
additional biomarker targets for neurodegeneration. More-
over, in DLB, AD, and FTD patients, lysosomal enzyme
activities in CSF demonstrated a very speciﬁc pattern of
decrease, in which only DLB showed signiﬁcant decreases
in CSF activity of α-mannosidase, β-mannosidase, GBA,
galactosidase, and β-hexosaminidase, whereas in AD and
FTD, only CSF α-mannosidase activity was signiﬁcantly
diminished [118]. In DLB, CSF GBA activity showed the
greatest magnitude of decrease, reinforcing its importance
in the LBD, but also noteworthy is the fact that AD and
FTD showed decreased α-mannosidase activity, suggesting
that this might be another important factor in lysosomal
dysfunction in neurodegeneration. Indeed, these promising
candidates need to be investigated further to establish diag-
nostic accuracy in terms of disease speciﬁcity and sensitivity
in cohorts of PD, DLB, and other dementing disorders.
6.Miscellanous CandidateBiomarkers
6.1. Inﬂammatory Cytokines. Polymorphisms in proinﬂam-
matory cytokine genes including IL-1α,I L - 1 β,a n dT N F -
α are associated with increased risk in AD [119]. In PD,
several case control genetic analyses have demonstrated that
homozygous carriers of the IL-1β−511 and TNF-α−308
promoter region variants have increased disease risk [120,
121], and that earlier age at onset in PD was associated
with IL-1β−511 homozygosity at allele 1 [122]. But as
yet, no such genetic alterations in cytokines genes have
been reported in DLB. Similar to Aβ-induced upregulation
of inﬂammatory cytokines in AD, soluble secreted α-syn
in the extracellular space in LBD might also induce the
productionofavarietyofneuroinﬂammatory mediatorsinto
the extracellular ﬂuid. For instance, microglial activation in
response to stimulation by secreted α-syn from cultured cells
and from overexpression in transgenic mouse models occurs
in a dose-dependent manner, causing release TNF-α,I L - 1 β,
and IL-6 [123]. Because secreted CNS cytokines are readily
detected in CSF, they have been extensively examined as
potential disease biomarkers. IL-1β,I L - 2 ,I L - 6 ,a n dT N F -
α are all upregulated in PD brain, as well as in CSF
from PD patients [124–126], and Chen et al. showed that
plasma IL-6, but not IL-1β,T N F - α,o ro t h e ra c u t ep h a s e
reactants, predicted risk for future PD in males [127]. In
terms of DLB, CSF IL-1β levels, which were relatively low,
did not diﬀer compared to AD or normal controls and
could not distinguish them apart. Comparable increases in
CSF IL-6 levels were found in AD and DLB, but again not
signiﬁcantly diﬀerent from each other to be of diagnostic
value [128]. Indeed, the neuroinﬂammatory cytokines may
be important as a pathogenetic response to CNS injury
caused by accumulation of amyloidogenic proteins, but their
role as biomarkers for the LBD, especially for DLB, is still
unclear.
6.2.Neuroﬁlament Proteins. Disorganization andbreakdown
in the cytoskeletal network occurs in various LBDs and
other neurodegenerative diseases, and as discussed, gamma-
synuclein and proteolytic degradation of the cytoskeleton
may be involved. As a result, a failure of normal axonal
transport results from the accumulation of disrupted neu-
roﬁlament molecules within the neuropil, causing neuronal
demise[129].Recently,amutationintheNEFMgeneencod-
ing the rod domain 2B of neuroﬁlament M (NF-M) which
causes aberrant NF assembly was identiﬁed in a single early-
onset PD patient [130]. It is recognized that in addition to
α-syn, three types of NF protein also comprise the structure
of Lewy bodies [131]. Upon cell death or axonal damage,
accumulatedneuroﬁlamentleaksintotheextracellularspace,
subsequently appearing in CSF and perhaps other peripheral
ﬂuids. Elevated CSF NF protein was reported in MSA and
PSP, but not in PD, and this was suggested to clinically
aid in diﬀerentiating parkinsonian syndromes [132]. CSF
NF protein was also measured in dementia, and although
increased levels were observed in DLB, late-onset AD, and
FTD, there were no diﬀerences among them [28]. Therefore,
because cytoskeletal abnormalities are present in many
neurodegenerative dementias as well as in PD, NF protein
may be more a reﬂection of nonspeciﬁc alterations in
neuronal and axonal function, which does not appear to able
to clinically separate DLB from other disorders.
6.3.Brain Neurotransmitter AlterationsinCSFand byImaging
Modalities. Severe cortical cholinergic deﬁcits originating
from deﬁciencies in the nucleus basalis of Meynert are
characteristic of AD brain, but studies have shown that
cholinergic deﬁcits are perhaps more severe in DLB brain
[5]. This suggests that measurement of cholinergic activity
and/or acetylcholine (ACh) might be developed into a
potential biomarker for the LBDs. Indeed, early attempts to
quantify ACh or its major metabolite, choline, have shown
baseline levels to be low and perhaps diﬃcult to measure
accurately. In AD, CSF ACh was reported to be signiﬁcantly
lowerthancontrollevels[133],whileinPDandHuntington’s
diseasepatients,despitesomecholinergicdeﬁcit,lumbarCSFInternational Journal of Alzheimer’s Disease 9
ACh and choline levels did not diﬀer from normal [134]. No
studies have directly examined CSF cholinergic levelsin DLB
or LBDs, but recently, Shimada and colleagues employed
positron emission tomography (PET) mapping ofbrain ACh
activity in DLB and PDD patients and normal controls and
demonstrated a marked reduction in cholinergic activity
in medial occipital cortex of DLB and PDD, greater than
that observed in PD patients without dementia [135]. Some
correlation of mapped cholinergic activity with cognitive
decline measured by the Mini-Mental State Exam was also
found. Although preliminary, this has potential to be a more
practical and sensitive cholinergic biomarker for LBD.
Because of similar nigrostriatal loss to PD, a relative
dopaminergic deﬁciency also exists in DLB and LBDs. CSF
dopamine (DA) and its metabolites have been investigated
previously in PD, and recently, Lunardi et al. showed
diﬀerences in CSF DA and its metabolites, homovanillic
acid (HVA) and dihydroxyphenylacetic acid (DOPAC), in
PD patients, demonstrating early-stage dopaminergic loss
and a correlation with the development of dyskinesia [136].
In DLB, HVA levels were signiﬁcantly reduced compared
with AD, separating the disorders [137]. Similar to cholin-
ergic activity, imaging modalities may also contribute to
the assessment of dopaminergic function in the LBDs. In
a small study, striatal DA uptake as measured by 18F-
ﬂuorodopaPET was decreased in both caudate and putamen
in DLB as compared with AD patients and controls [138].
Also, DA transporter loss was determined across multi-
ple studies using 123I-2β-carbometoxy-3β-(4-iodophenyl)-
N-(3-ﬂuoropropyl) nortropane ligand with single-photon
emission computed tomography (123I-FP CIT SPECT) and
demonstrated signiﬁcant loss of caudate and putaminal
DA transport compared with AD and control levels [139–
141]. A larger phase III, multicenter study of 123I-FP CIT
SPECT in possible and probable DLB patients and non-DLB
comparators (mostly AD) demonstrated a mean sensitivity
of 77.7% for detecting clinically probable DLB, with a
speciﬁcity of 90.4% and 85.7% overall diagnostic accuracy
[141]. 123I-FP CIT SPECT DA transporter imaging greatly
enhanceddiagnosticaccuracyfor DLBoverclinicaldiagnosis
alone when coupled with autopsy conﬁrmation, raising
sensitivity for DLB from 75% to 88% and speciﬁcity from
42% to 100% [139]. Furthermore, DA transporter loss in
the caudate may also be inversely associated with depression,
apathy, and delusions in DLB patients [142].
6.4. Miscellaneous Imaging Biomarkers in LBD
6.4.1. MIBG Scintigraphy as a DLB Biomarker. Autonomic
failure is a common clinical ﬁnding in LBD, including PD
and DLB, but not in non-LBD dementias, and therefore
it has been investigated as an alternative biomarker for
the diagnostic separation of DLB from other dementias.
Abnormal autonomic function can be determined using car-
diac 123I-meta-iodobenzyl guanidine(123I-MIBG)imaging,a
technique which assesses cardiac sympathetic nerve function
in both cardiac and neurological disorders by measuring
the uptake of 123I-MIBG, a norepinephrine analogue [143].
In the last decade, a series of Japanese studies consistently
demonstrated delayed heart to mediastinum ratio (H/M) of
123I-MIBG uptake in DLB compared with AD and controls
[143–146]. 123I-MIBG scintigraphy was found superior to
brain perfusion SPECT imaging [147]. Estorch et al. further
showed that in dementia patients followed for four years
before “ﬁnal diagnosis,” 123I-MIBG imaging distinguished
DLB from other dementias with a sensitivity of 94%,
speciﬁcity of 96%, and a diagnostic accuracy of 95% [148].
Finally, consistent with autonomic dysfunction in DLB, both
early and delayed H/M 123I-MIBG uptake were signiﬁcantly
associated with the presence of orthostatic hypotension in
DLB patients and discriminated DLB from AD even in the
absence of parkinsonism [149].
6.4.2. Other Structural and Functional Imaging Biomarkers.
Various magnetic resonance (MR) imaging modalities have
been explored in DLB and PDD, including volumetric
imaging, diﬀusion tensor imaging, and proton magnetic
resonance spectroscopy (reviewed in Watson et al.) [150],
and although not directly useful as biomarkers at present,
they have revealed insights in the pathobiology of LBDs.
Using conventional MRI techniques such as voxel-based
morphometry and region of interest analysis, some degree
of diﬀusion or focal frontal and parietal atrophy has been
observed [151]. Atrophy has been rated at 1.4% per year
in DLB brain [152], 1.31% per year in PDD, and 0.31%
per year in PD [153]. Not surprising is the fact that unlike
ADbrain,medial temporalstructuresare relativelypreserved
in DLB and PDD, with global hippocampal loss at about
10–20% compared with controls and about 21–25% in AD
[154]. Diﬀusion tensor imaging, an MR technique mapping
brainmicrodiﬀusionofwaterinthedirectionofwhitematter
tracts, has shown decreased fractional anisotropy of water
movement in DLB in the precuneus and posterior cingulate
areas, perhaps highlighting their role in DLB pathogenesis
[155].
Brain perfusion SPECT (99mTc-HMPAO SPECT) has
been evaluated in its ability to diagnostically separate DLB
from AD, and in AD, reduced relative cerebral blood
ﬂow (rCBF) in the frontal, and medial temporal regions
is characteristic, whereas in DLB, occipital hypoperfusion
is often observed [156]. Colloby et al. applied statistical
parametric mapping to SPECT imaging of DLB patients,
more precisely showing large perfusion deﬁcits in the left
medial occipital gyrus and the bilateral central, inferior
parietal, precuneate, superior frontal and cingulate regions
on the brain, which are functionally consistent with frontal-
executive and visuospatial deﬁcits in DLB [157]. Across
studies, sensitivity ranged from 65 to 85% and speciﬁcity
from 85–87%, which appears less robust as a potential
imaging marker compared with other methods.
6.5. Other PD Genes and Their Protein Products as Possible
DLB Markers. Aside from α-syn and DJ-1, numerous other
mutations have been associated with familial early-onset PD
and possibly LBD (Table 1). Among these gene products10 International Journal of Alzheimer’s Disease
are parkin (PARK 2), UCHL-1 (PARK 5), PINK1 (PTEN-
induced putative kinase 1; PARK 6), and LRRK2/dardarin
(PARK 8) [158]. Indeed, none of these mutations have
yet been associated with prototypic LBD pathology, and it
remains to be determined whether they actually represent
LBDs or separate diseases with parkinsonian phenotype.
Furthermore, no studies have addressed their role as bio-
logical markers of disease, but since both synucleins and
DJ-1 are detected in CSF and peripheral ﬂuids, it seems
plausible that the protein products of other dominant genes
in PD could be peripheral biomarker candidates for DLB
and other LBD. Parkin, UCHL-1, and PINK1 genes, like
DJ-1, all encode proteins important in neuroprotection in
terms of maintaining protein homeostasis and preventing
stress-related cellular damage, and mutations in these genes
cause a loss of these critical functions. Leucine-rich repeat
kinase 2 (LRRK2/dardarin), on the contrary, is linked with
autosomal-dominant late-onset PD, and mutations result in
a toxic gain of function.
LRRK2/dardarin is a kinase consisting of multiple func-
tional domains, and recent evidence suggests that physio-
logically, its principal function may be to regulate neurite
outgrowth.Expression inculturedneuronsofseveral LRRK2
mutations associated with familial PD, such as G2019S,
increased kinase activity and signiﬁcantly reduced neurite
outgrowth, whereas expression of a dominant-negative
mutation,K1906M,markedlyincreased neuritelength[159].
PD-associated mutations also generated tau-positive axonal
inclusions in cultured neurons, suggesting that LRRK2 may
be linked to abnormalities in tau. Indeed, expression of
mutant G2019S LRRK2 in Drosophila caused activation
of the Drosophila GSK-3β homolog and promoted tau
hyperphosphorylationleadingtomicrotubulefragmentation
and dendritic pathology [160]. Similar tau hyperphosphory-
lation was also present in transgenic mice expressing G2019S
LRRK2, and expression of both wild-type human LRRK2
and G2019S mutant LRRK2 caused abnormal dopaminergic
transmission [161]. LRRK2 may also interact with α-syn,
another dominantly inherited PD gene, to exert its eﬀect.
Lin et al. showed that overexpression of LRRK2 with A53T
mutant α-syn in transgenic mice worsened neurodegenera-
tion, while ablation of LRRK2 expression suppressed α-syn
aggregation and pathology [162], and α-syn also activates
GSK-3β in mice causing tau hyperphosphorylation [163],
indicating that LRRK2, α-syn, and tau alterations may all be
linked in the same pathway, perhaps with LRRK2 upstream
of these events. Although early, evidence has indicated that
LRRK2 is also a component of LB in PD and DLB brains
[164], and that LRRK2 and α-syn interact in DLB brain
and coimmunoprecipitate in cultured cells after oxidative
stress challenge[165],suggestingthattheLRRK2mayalso be
important in DLB pathogenesis. Interestingly, genome-wide
association studies (GWASs) in a European cohort demon-
strated that LRRK2, α-syn, and tau are loci associated with
PD risk [166], but examination of tau in a Japanese GWAS
cohort failed to identify it as a PD risk locus [167], showing
a population diﬀerence with regard to this locus. Certainly,
population diﬀerences might apply to all risk loci examined
f o rP Da n dL B D ,a n di ti si m p o r t a n tt od e t e r m i n ew h e t h e r
the relationship among LRRK2, α-syn, and tau in PD, DLB,
and other LBD is also inﬂuenced by population diﬀerences.
Theseﬁndings makeLRRK2/dardarinanattractivecandidate
for examination as a potential biomarker, and if identiﬁed in
CSF or peripheral ﬂuids, they might be used with α-syn and
tau as combined biomarkers.
Furthermore, emerging evidence is redeﬁning the roles
of PINK1 and parkin in PD pathogenesis. Because energy
generation is critical for cellular function, mammalian cells
are highly dependent on mitochondria [168]. Depolariza-
tion and morphological defects characterize damaged or
impaired mitochondria which are targeted for removal
through mitophagy, a highly specialized form of autophagy
in which parkin and PINK1 play a crucial role (reviewed by
Vives-Bauza and Przedborski) [169]. In this process, PINK1
cleavage is inhibited by the loss of mitochondrial membrane
potential, causing its lengthening and the recruitment of
cytosolic parkin [170, 171]. Voltage-dependent anion chan-
nel 1 and other outer mitochondrial membrane proteins
are then ubiquitinated in a parkin-dependent manner, and
this in turn recruits the binding of adapter proteins such
as p62 and histone deacetylase 6 to initiate autophago-
some assembly around the damaged mitochondrion and
subsequent removal [169]. Of relevance to PD, mutant
PINK1 and mutant parkin both cause motor dysfunction,
dopaminergic loss, and abnormal mitochondrial morphol-
ogy in Drosophila [172]. In this paradigm, loss of function
PINK1 mutants are rescued by concurrent overexpression
with wild-type parkin but not vice versa, indicating that
parkin speciﬁcally acts downstream of PINK1. Also, parkin
mutations have been shown to interfere with ubiquitination
and thedownstream steps in normal mitophagy[173].Thus,
PD, and possibly related dementias, might be a result, to
some extent, of defective mitophagy due to loss of function
in PINK1 and parkin such as found in autosomal dominant
early-onset PD.
Although LRRK2, parkin, PINK1, and UCHL-1 have
not yet been identiﬁed in peripheral ﬂuids, PINK1 and
parkin may be a promising candidates. Unexpectedly, both
PINK1 and parkin, which are normally cytosolic or tar-
geted to mitochondria, were localized extracellularly in AD
and multiple sclerosis brain, and colocalized with amyloid
plaques, reactive astrocytes, as well as amyloid-aﬀected
vessels [174, 175]. This suggests that both PINK1 and parkin
are actively released from neurons and glia in response to
injury andmightbeupregulatedinCSFandperipheralﬂuids
during neurodegeneration. Interestingly, given a role in
mitophagy, they might also be a CSF or peripheral reﬂection
of mitochondrial health and turnover. It remains to be seen
whether these gene products can be detected in biological
ﬂuids such as CSF as potential biomarkers in PD and LBD.
7.Unbiased Methodsin
LBD BiomarkerDiscovery
7.1.Genomicsin PDand LBDs. Asdetailedabove,traditional
methods for molecular biomarker determination have been
derived from targeted analyses of candidate genes/mutationsInternational Journal of Alzheimer’s Disease 11
and corresponding proteins in brain and body ﬂuids such as
CSF and blood, with the subsequent exploration of mecha-
nisms in cell culture and animal models. An emerging alter-
nate approach has been to evaluate genomes and proteomes
with regard to speciﬁc neurodegenerative diseases and their
components in an unbiased manner to yield a number of
potential pathogenetic, therapeutic, and biomarker targets
for further validation. With regard to the genomic analysis
of the LBDs, gene expression proﬁling has proved to be
a promising tool. Scherzer et al., for instance, examined
transgenic Drosophila expressing the human α-syn gene and
performed temporal proﬁling of resultant gene expression
[176]. They demonstrated a number of changes, including a
downregulation of phospholipase A2 and other lipid genes,
downregulation of several mitochondrial respiratory chain
molecules,and alteration in membrane transport and energy
genes such as voltage-gated calcium channel and lysosomal
ATPase, suggesting that mitochondrial integrity might be
aﬀected by α-syn overexpression.
In Parkinson’s disease brain, RNA from populations
of mesencephalic dopaminergic neurons with and without
LB were isolated by immunolaser capture microdissection,
ampliﬁed by polymerase chain reaction and expressed [177].
Interestingly, upregulation of the ubiquitin-speciﬁc protease
8 in LB-containing neurons indicated cellular damage and
increased levels of ubiquitination in LB, whereas non-
LB-bearing neurons showed increased expression of novel
cytoprotective genes such as bullous pemphigoid antigen 1,
an HSP-70-like gene (STCH) and Kelch-like 1. Although
promising, further genomic proﬁling studies in DLB, PDD,
and other LBD are needed to expand the range of novel gene
targets for examination and validation.
7.2. ProteomicProﬁling in PD and LBDs. As a complementto
gene expression proﬁling and genomic methods, proteomic
proﬁlinghasalsoassumedagreaterimportanceinbiomarker
discovery for neurodegeneration with relevance to the LBD.
Advances in methodologies such as 2-dimensional gel elec-
trophoresis (2-D GE), liquid chromatography (LC), high-
resolution mass spectrometry (MS), and quantitative pro-
teomics allow analysis of static or condition-dependent pro-
tein structure and function associated with PD and LBD in a
varietyofsampletypessuchasbrainorbodyﬂuids(reviewed
inShietal.2009)[178].InmicetreatedwithMPTP, aspeciﬁc
mitochondrial toxin,isotope-codedaﬃnity tagassay ofbrain
tissue followed by MS analysis revealed 100 proteins with
signiﬁcantlyalteredlevelsincludingmanymitochondrialand
metabolic molecules, βAPP and DJ-1 [179].
Basso et al. ﬁrst examined the proteome of the substantia
nigra from Parkinson’s disease brain and age-matched
controls [180]. Using 2D GE and peptide ﬁngerprinting, of
the 44 expressed proteins, 9 proteins diﬀered in PD versus
controls, including oxidative and mitochondrial proteins
such asperoxiredoxinII, mitochondrial complexIII,calcium
channel, and others. A subsequent study in PD brain showed
decreased frontal cortex levels of mortalin, a novel mito-
chondrial chaperone protein with roles in energy generation
[181]. Inaddition, LBsisolated by laser-capture microdissec-
tion, were analyzed by LC/MS and ultimately demonstrated
156 candidate proteins involved in ubiquitin-proteasome
system and synaptic function, from which the heat shock
cognate-71, a chaperone involved in neurodegenerative
disease, was identiﬁed and validated as a candidate target
[182]. Abdi and colleagues carried out proteomic evaluation
of CSF from AD, PD, and DLB patients and normal control
individuals, using chromatography, MS, and isobaric tagging
for relative and absolute quantiﬁcation (iTRAQ), identifying
numerous candidate proteinsrelated to PDand DLB,such as
lipoproteins ApoC1 and ApoH [183]. Lastly, using surface-
enhanced laser desorption/ionization-time of ﬂight (SELDI-
TOF) MS analysis of serum from DLB patients compared
to AD, a combination of protein peaks provided the ability
to separate DLB from non-DLB cases, with a sensitivity of
83.3% and a speciﬁcity of 95.8% [184]. Given promising
ﬁndings, further exploration of the proteomics of the LBDs
is warranted, and perhaps consideration should be given
to determining whether combining various genomic and
proteomic methods will be of value.
8.Conclusions
Over the last decade, tremendous advances have been
made in understanding the pathogenetics of PD, PDD,
and DLB, which has revealed not only the genetic basis
of these disorders, but also related mechanisms common
to all the LBD. In parallel, these discoveries have been a
catalyst for translating and developing many of the involved
proteins into promising biomarkers for disease. A common
theme centers on genes that drive a complex network of
synergistic and opposing cellular actions underlying path-
ogenesis. Aggregation of α-syn, the main constituent of
intracellular LBs, results in toxic oligomers and protoﬁbrils
which not only act intracellularly, but also are actively and
passively released into the extracellular environment causing
damage to surrounding tissue. Proinﬂammatory cytokines
such as interleukins are also produced which perpetuates
the inﬂammatory cascade. On the contrary, DJ-1, PINK1,
parkin, and perhaps others molecules are upregulated to
oppose cellular protein misfolding and oxidative stress and
maintain mitochondrial function, while autophagy mech-
anisms attempt to limit the toxic eﬀect of synucleins and
other toxins by lysosomal engulfment and digestion. Much
of this is reminiscent of a relatively new concept applied
to infectious diseases and mechanical tissue injury termed
“damage-associated molecular patterning” (DAMP), which
isan evolvedsystemtorecognize, contain,andrepairdamage
to cells and tissues. It is characterized by the abnormal
release of molecules normally conﬁned and operating within
healthy cells or from foreign pathogenic agents, that when
released into the extracellular space activate receptors and
pathways leading to inﬂammation and multiplying cellular
damage (reviewed by Bianchi) [185]. In this regard, events
in the pathogenesis of PD, DLB, and related disorders may
represent a novel variation of the DAMP response, and in a
sense, biological ﬂuid markers are therefore a measurement
of DAMP activity as it relates to neurodegeneration.
Despite progress in developing biological markers for
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of disorders remains challenging. The need for highly
sensitive and speciﬁc biomarkers that accurately mirror
the underlying pathogenetic features of these disorders
demands not only that more advanced detection methods be
devised and validated in large sample populations, but also
that novel biomarker candidates be selected for evaluation
based on rational selection from the multiple-associated
gene-mechanism associations in the LBD. Gene products
including β-a n dγ- s y n u c l e i n ,G B A ,p a r k i n ,a n dP I N K 1n e e d
to be examined in CSF, blood, and even urine to conﬁrm
their presence in biological ﬂuids and threshold of detection.
Alterations in the levels of these putative biomarker candi-
dates in CSF and blood can provide further insight into the
rolethesemechanisms mayplayindiseaseandalsotheability
of the potential biomarker to reﬂect resulting CNS changes.
To better understand the relationship of gene mutations,
mechanisms, and disease biomarkers in LBD, it would be
of great interest to determine whether the levels of these
putative biomarkers in CSF and peripheral ﬂuids are altered
in patients with known PD, DLB, and LBD mutations. It is
likely that combinations of multiple peripheral biomarkers
could be needed to monitor the various mechanistic aspects
underlying the LBD, but the optimal combination has
yet to be determined. Furthermore, both existing imaging
modalities as well as novel imaging techniques to detect
speciﬁcmolecularbiomarkertargetswillgreatlycomplement
peripheral biomarkers. New speciﬁc therapies for the LBD
yet to be developed will probably target one or more of the
multiple pathways described above, and indeed, this could
determine which biomarker or combination of biomarkers
would be appropriate as a therapeutic endpoint. Studies
are also needed to establish which biomarkers will fulﬁll
the criteria of minimum sensitivity and speciﬁcity for the
LBD for consistent and reproducible diagnostic use in
presymptomatic disease detection and also serve as robust
tracking tools and endpoints in monitoring the eﬃcacy of
future LBD therapies.
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